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Aberrant DNA methylation of alternative promoter of DLC1 
isoform 1 in meningiomas
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of meningiomas and normal meninges. The DLC1 isoform 
1 was found as the most expressed in normal control tis-
sue and was significantly downregulated in meningiomas. 
Transfection of KT21 meningioma cell line with shRNA 
targeting DLC1 isoform 1 resulted in increased activation 
of RHO-GTPases assessed with pull-down assay, enhanced 
cell migration observed in scratch assay as well as slight 
increase of cell metabolism determind by MTT test. Results 
indicate that isoform 1 represents the main pool of DLC1 
protein in meninges and its downregulation in meningio-
mas is associated with hypermethylation of CpG dinucleo-
tides within the corresponding promoter region. This iso-
form is functional GAP protein and tumor suppressor and 
targeting of its expression results in the increase of DLC1 
related cell processes: RHO activation and cell migration.
Keywords DNA methylation · Alternative promoter · 
DLC1 · RHO-GTPases · Meningioma · Epigenetic · 
Expression
Introduction
Meningiomas are am ng the most frequent primary intra-
cranial tumors in adults. Most are benign (WHO grade I) 
neoplasms and only some transform to more aggressive 
subtypes (grade II or III) [1 ]. They represent an impor-
tant clinic l problem, as tumor recurrence is observed in 
approximately 20 % of all patients and in 30–40 % of those 
with incompletely resected tumors [2]. Standar reatment 
involves surgical resection with optional radiosurgery or 
radiotherapy in cases of incomplete resection. Despite the 
fact that meningiomas are common intracranial tumors, rel-
a ively little is known about their molecular pathogenesis as 
compared to other tumors diagnosed with similar frequency. 
Abstract DLC1 encodes GTPase-activating protein 
with a well-documented tumor suppressor activi y. This 
gene is downregulated in various tumors through aber-
rant promoter hypermethylation. Five dif erent DLC1 
isoforms can be transcribed f om alternative promoters. 
Tumor-related DNA methylation of the DLC1 isof rm 1 
alternative promoter was identified as being hypermethyl-
ated in meningiomas in genome-wide DNA methylation 
profiling. We determined the methylation pattern of this 
region in 50 meningioma FFPE sam les a d sectio s of 6 
normal meninges, with targeted bisulfite sequencing. All 
histopathological subtypes of meningiomas showed imilar 
and significant increase of DNA methylation levels. High 
DNA methylation was associated with lack of DLC1 pro-
tein expression in meningiomas as etermined by immu-
nohistochemistry. mRNA expression levels of 5 isoforms 
of DLC1 transcript were measured in an additional series 
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Materials and methods
Patients and tissue samples
Archival tissue meningiomas samples from patients who 
underwent surgical tumor resection at the Cancer Center 
and Institute of Oncology in Warsaw were used for DNA 
isolation and genomic sequencing. Fifty patients with spo-
radic meningiomas (33 WHO grade I, 11 grade II and 6 
grade GIII) were enrolled in the study. All tissue samples 
were histopathologically examined involving a review of 
diagnosis and selecting representative tissue section suitable 
for molecular analysis. Patients’ characteristics are listed in 
Table 1 . Control samples of meninges were harvested at 
non-neurooncological neurosurgical procedures while duro-
plasty was an element of those procedures.
Formalin-fixed and paraffin-embedded (FFPE) tissue 
samples were manually macrodissected where DNA was 
isolated using a QIAmp DNA mini kit (Qiagen). In order 
to isolate high quality RNA for qRT-PCR analysis, 16 
meningioma Sections (15 GI, 1 GII tumors) and 4 normal 
meninges sections were collected and snap frozen in liquid 
nitrogen. Total RNA was isolated using the RNeasy Mini 
(Qiagen).
Approval was obtained from the Institutional Ethics 
Committee for experimenting on human patient samples.
Genome-wide DNA methylation analysis
The HumanMethylation 450K Infinium Methylation Bead-
Chip (Illumina) was used to profile whole-genome DNA 
methylation of 8 benign (GI), 5 atypical (GII) and 4 anaplas-
tic meningiomas (GIII) as well as 4 normal meningeal sam-
ples. Laboratory procedures were performed by the AROS 
Applied Biotechnology service. Genomic DNAs were 
bisulfite-converted, using the EZ-96 DNA Methylation kit 
(Zymo Research, Orange, CA, USA). Probes with missing 
intensity signals were discarded (9541 probes out of 485, 
578). Probes were divided into design classes and annotated 
to genome location according to the lluminaHumanMeth-
ylation450k. db library. Intensities were normalized with 
the BMIQ package (version 1.3) using default parameters 
[14 ]. Probe mapping to differentially methylated sites were 
selected according to the P value from the t est (Welch vari-




Primers for targeted bisulfite sequencing of two DLC1 pro-
moter regions were designed and validated by Zymo Research 
and were synthesized by Integrated DNA Technologies 
Some important tumor driver genes have been identified 
including the most common NF2 r TRAF7, but the role of 
epigenetic aberrations is still poorly under tood.
The DLC1 (Deleted in Liver Cancer 1) g ne e odes 
GTPase-activating protein (GAP) belonging to the RhoGAP 
protein family. These proteins act as molecul r switch  
through the regulation of small GTP-binding proteins. 
RhoGAPs take part in cell signaling and re inv lved in 
regulating a variety of cellular proteins [3].
DLC1 is well described as a tumor suppressor that pr-
vents cell migration, invasion and metastatic progression in 
various cancer types [4, 5]. The expression of this gene wa  
shown to be notably reduced in various tumors. Genomic 
mutations and aberrant promoter me hy ation have also 
been proved to be implicated i  gene silencing. In some 
cancers, the loss of DLC1 expression was shown to be of 
prognostic value [4, 6].
An important issue not considered previously in most can-
cer studies on DLC1, is that multip e tran cript variants of 
this gene have been identified. Five different transcripts are 
encoded in the DLC1 locus which are expressed through alter-
native promoters and undergo alternative splicing (Fig. 1a).
Interestingly, the differe t short DLC1 alternative va i-
ants are generated from different parts of the gene body and 
encode varying protein contents.
Alternative DLC1 variants have been shown to be 
expressed in humans and mice [7–9] However, various 
human tissues show different levels of mRNA in individual 
variants [7]. Alternative promoters of different transcript 
isoforms seem to be regulated epig netically [7]. The vast 
majority of previous researc  on DLC1’s role in cancer have 
not addressed the issue of mul ip e transcript variants or 
were only focused on DCL1’s role in variant 2. Expression 
of different alternative DLC1 transcr pts was considered 
only in a very few cancer studies [7, 9].
DLC1 downregulation in mening omas was reported once 
in a study on a small series of samples; 6 tumor samples a d 
4 normal meninges, however, no DNA methylation of the 
gene promoter have been found [10 ]. It is also known that 
DLC1 mutations have not been identified in meningiomas 
for whole exome sequencing studies and no mutations of hi  
gene have been reported in the COSMIC datab s [11 , 12].
In contrast to the lack of reported DLC1 prom ter meth-
ylation in meningiomas, we identified 5′ region of DLC1 
as being frequently hypermethyl ted in this tumor. This 
prompted us a deeper investigation of DNA DLC1 promot r 
methylation and its possible role in gene expression.
The presented study numbers DLC1 tra scription var a t  
according to the Refseq database using sequence accession 
numbers as follows; DLC1 variant 1 (DLC1-v1)-NM_182643, 
variant 2 (DLC1-v2)-NM_006094, variant 3 (DLC1-v3)-
NM_024767, variant 4 (DLC1-v4)-NM_001164271.1 and 
variant 5 (DLC1-v5)-NM_001316668 [13 ].
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and CV < 10  % for duplicates). DNA samples were bisul-
fite treated with the EZ DNA Methylation-Direct™ Kit. 
Targeted sequencing was done using the Fluidigm Access 
Array with Zymo Research’s Targeted sequencing service 
protocol. Sample loading, harvesting, and pooling was 
(IDT). The primers’ quality control (QC) tested for specific 
amplification of 1 ng bisulfite-treated DNA (in duplicate) 
using converted DNA QC criteria, which included robu t 
and specific amplification of the bisulfite primers on real-





Fig. 1 aGenomic location of 5 transcription variants of DLC1. b, c 
DNA methylation level of the DLC1 locus at CpGs measured by the 
HumanMethylation 450K array (Illumina) in meningiomas and normal 
meninges. Each blue/r d dotrepresents an individual CpG. d DNA 
methylation levels in meningiomas of different grade at CpGs within 
differentially methylated regions (DMR) (HumanMethylation 450K 
microarray data). d, e DNA methylation level of DMR at 5′ region of 
DLC1 locus determined by targeted bisulfite sequencing of two PCR 
amplicons. d C mparison of average methylation levels of each CpGs 
in meningiomas and normal samples. Each dot represents the mean 
value and rror bars rep esent standard errors of the mean. e Compari-
on of av age DNA methylation levels for two amplicons in normal 
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well format and Applied Biosystems 7900HT Fast Real-
Time PCR System (Applied Biosystems) with the Sen-
simix SYBR kit (Bioline), according to manufacturer’s 
recommendations in a volume of 5 µl. RPL32 was used 
as reference, as this gene was previously identified as the 
most stable for meningiomas and normal arachnoid [15 ]. 
Standard curves based on amplification of known cDNA 
template concentrations were used for calculating PCR 
efficiency. Because we were not able to design an effective 
qRT-PCR primer specific for DLC-v1 exclusively, we used 
qRT-PCR primers specific for both DLC1-v1 and DLC1-
v3. The expression of DLC1-v1 was calculated by the 
subtraction of the result obtained with primers unique for 
DLC1-v3 from the result obtained with the primers com-
mon for variant 1 and 3. The PCR primers’ sequences are 
presented in Table 2.
Immunohistochemistry (IHC)
Immunohistochemical staining was performed on 4 μm 
formalin-fixed, paraffin-embedded tissue sections of 18 
meningiomas (5 meningothelial GI, 4 fibrous GI, 4 atypi-
cal GII and 5 anaplastic GIII tumors) using the Envision 
Detection System and DAB reagent (DAKO). Sections 
were deparaffinized with xylene and rehydrated in a series 
of ethanol solutions decreasing in concentration. Heat-
induced epitope retrieval was carried out in a Target 
Retrieval Solution pH 6 (DAKO) in a 96 °C water bath 
for 20 min. For cooling down, slides in retrieval solutions 
were kept at room temperature for 30 min and hey we e 
treated for 5 min with an Endogenous Peroxidase Blocker 
(DAKO). Slides were then incubated with polyclonal anti-
body against DLC1 (PA5-28443, Pierce/Thermo Scien-
tific) at 1:250 dilution for 60 min at room temperature and 
subsequently labelled with the Envision Detection System 
(DAKO). This antibody was produced using immunogen 
peptide corresponding to a region within amino acids 1 and 
43 of Human DLC1-v1. Therefore it recognizes two pro-
tein isoforms: DLC1-v1 (170 kDa) and DLC1-v3 (51 kDa) 
and do not detect the remaining DLC1 variants lacking 
N-terminal sequence used for immunization. The colour 
reaction product was developed with 3,3′-diaminobenzi-
dine, tetrahydrochloride (DAB) (DAKO) as substrate. Tis-
sues were then counterstained with Mayer’s haematoxylin, 
dehydrated and cover-slipped using a permanent mounting 
solution (Toluene-Free Mounting Medium, Dako). Positive 
and negative controls were included. Staining intensity was 
assessed by a four-grade scale: 0—lack of expression, 1—
weak expression, 2—moderate expression and 3—strong 
expression. A section of normal colonic mucosa sample 
was used as the technical positive control. The stained tis-
sue slides were examined by the investigator blinded to the 
DNA methylation results.
performed according to the manufacturer’s protocol (Flu-
idigm). Amplicons were pooled, diluted 1:100 and then 
amplified using barcoded adaptor-linkers from Fluidigm, 
according to manufacturer’s protocols. Re ctions were 
cleaned up using the DNA Clean and Co centrator™-5 
and products were normalized by concentration and then 
pooled. The library was denatured, iluted, and sequenced 
on the Illumina MiSeq according to th  manufacturer’s pro-
tocols. The sequencing run wa  a 150-base paired-end run. 
Two amplicons for DLC1 pr moter were analyzed: ampli-
con 1 (chr8:13372333–13372641, hg19) and amplic  2 
(chr8:13372933–13373241, hg19).
Quantitative PCR expression assessment (qRT-PCR)
1  µg of each RNA sample was subjected to revers  tran-
scription with the Transcriptor First Strand cDNA Syn-
thesis Kit (Roche). qPCR was undertaken usi g the 384 
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into double-stranded DNA insert and cloned into pGFP-B-
RS vector, digested with BamHI and HindIII, according to 
manufacturers’ recommendations. The construct sequence 
was verified with Sanger sequencing. Sequences of oligo-
nucleotides are provided in Table 2.
The cells at 70–80 % confluence were transfected using 
Lipofectamine 2000 (Life Technologies), according to the 
manufacturer’s instructions and harvested or assayed after 
culturing for 48 h. To assess transfection efficacy and to test 
the effect on DLC1-v1 expression transfected cells were 
analyzed and sorted using flow cytometer with cell sorter 
FACS ARIA III (BD biosciences).
In vitro assays
MTT assay, determining cell metabolic activity was per-
formed according to standard protocol. Briefly, cells were 
seeded onto 96-well plates in triplicates, transfected with 
shRNA encoding pGFP-B-RS vector or sh control vector 
and cultured for 48 h followed by MTT addition. After 4 h 
of incubation, 500 μL of DMSO was added to each well 
and absorbance intensity was recorded at 595 nm on Victor 
3 microplate reader (Perkin Elmer, Wellesley, MA, USA).
Scratch wound healing assay was performed based on 
previously published protocol. Cells were seeded onto 
10  cm plates, transfected with plasmid vectors at 90 % con-
fluence and cultured for 48 h. Scratch wounds were done 
by scraping the cell layer across each culture plate using 
the tip of 10 μl pipette. 10 fields were chosen, marked on 
the plates, visualized and captured by microscopy (magni-
fication ×40). The same 10 fields were captured after 16 h 
incubation. The cell migration distance was measured at 
each of 10 fields at the marked positions with the use of 
Quick Photo Camera 2.3 software (Promicra, Prague, Czech 
Republic). The migration distance was calculated as the dif-
ference between initial scratch width and width of cell free 
area after 16 h culturing at the marked positions.
Western blotting
Cells were lysed in ice cold RIPA buffer, incubated for 
30  min in 4 °C and centrifuged at 12,500 rpm for 20min at 
4 °C. Samples were resolved usi g SDS-PAGE and elect-
transferred to polyvinylidene fluoride membranes (PVDF) 
(Pierce/Thermo Fisher). DLC1 was detected with poly-
clonal anti-DLC1 antibody (PA5-28443, Pierce/Thermo 
Fisher), and secondary anti-rabbit antibody conjuga d to 
HRP (#7074, Cell Signalling). α-tubulin detected with poly-
clonal rabbit antibody (#2125, Cell Signalling) or β-actin 
detected with mouse HRP-conjugated ant body (#12262 
Cell Signalling) served as control. Visualization was per-
formed with the enhanced chemiluminescence method 
using WesternBright Quantum (Advansta, Menlo Park, CA, 
USA) and CCD digital imaging system Alliance Mini HD4 
(UVItec Limited, Cambridge, United Kingdom).
Silencing of DLC1 in KT21 meningioma cell line
KT21 meningima cells were used or DLC1 silencing an  
in vitro assays. The cells were grown on DMEM medium 
supplemented with 10 % FBS (L fe Technologies) a  37 °C 
and 5 % CO2 concentration.
Silencing of DLC1v1/v3 was achieved with the use 
of the pGFP-B-RS vector (OriGene Technologies, Inc., 
Rockville, MD, USA) encoding shRNAs complementary 
to 5′ regions of DLC1-v1 mRNA. Commercially avail-
able universal plasmid with scramb ed shRNA cassette (sh 
control): pGFP-B-RS-scrambled Non-Effective (OriGen  
Technologies, Inc., Rockville, MD, USA) served as a nega-
tive control (see Table 1  for details). The shRNA h irpin 
complementary to 25 bp at 5′ fragment of DLC1-v1 was 
designed using siRNA Wizard v3.1 (http://www.inv vogen.
com/sirnawizard/) and designed oligonucleotides included 
BamHI and HindIII restriction sites for cloni g. Synthetic 
78  bp-long single-stranded oligonucl o ides were annealed 
Table 2 Sequences of qRT-PCR primers and oligonucleotides encoding shRNA cassette targeting DLC1-v1/-v3 sequence
PCR primers
DLC1 variantForward 5′→3′ Reverse 5′→3′ Amplicon length (bp)
DLC1-v1/DLC1-v3GCG CCTATCTCGATCTTCT ACAATTAAAGGAGACCCTGGC 109
DLC1-v2 CTTCCCCACAGCGCTTC ACAAGCTTCCTTGGCTTCAA 98
DLC1-v3 CTTCCACTCCAGTAGCCAAT GCGAGAAAACAGAACCAAAATG 95
DLC1-v4 TGATCACGCAACAGTGAAACA ATCGATGGGGAACAGGAAAT 120
DLC1-v5 AGCGATCACATCAGGGACTC CCAATCACAAGCTTCCTTGG 105





*DLC1 complementary sequence is underlined
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enables DNA methylation to be compared for the entire 
gene, including two promoters of other DLC1 isoform  as 
well as evolutionary conserved intronic regions. The other 
DLC1 alternative promoters were found to be unmethylated 
in both tumors and control samples. Three additional CpGs 
at the different intronic regions of DLC1 locus had signifi-
cant differences in methylation level. Two of them revealed 
a slightly decreased DNA methylation level in tumors: 
cg26148020 (chr8:13136639; hg19) and cg26125690 
(chr8:13295113; hg19) with a difference of the mean beta-
value 0.270 and 0.227, respectively. One probe showed 
increased methylation: cg10941185 (chr8:12988517; hg19) 
with a difference of the mean beta-value 0.345. Generally 
meningiomas of different grades revealed very similar DNA 
methylation patterns at the entire DLC1 locus and no signifi-
cant differences between tumors of distinct histopathologi-
cal types were found.
To validate measured differential DNA methylation 
levels at DLC1-v1promoter, two amplicons covering this 
region were analyzed with single CpG resolution using tar-
geted bisulfite sequencing on a larger group of 50 tumor and 
6 normal samples. This confirmed increased DNA methyla-
tion in tumors vs. normal meninges and demonstrated very 
high DNA methylation in the vast majority of tumor sam-
ples. The mean DNA methylation levels of 3 CpGs within 
amplicon 1 were 60% in meningiomas vs. 19 % in samples 
of normal meninges (p = 0.0024), whereas the mean DNA 
methylation level in 5 CpG within the second PCR ampli-
con were 80 % in meningiomas vs. 37 % in the tissue of 
meninges (p = 0.0004). Details are presented in Fig. 1 d.
Analysis of DLC1 expression in meningiomas
We selected 18 meningioma tissue samples (4 meningo-
thelial, 4 fibrous, 5 atypical and 6 anaplastic meningiomas) 
for immunohistochemical staining to detect DLC1 pro-
tein expression using a polyclonal antibody. This antibody 
was produced using immunogen peptide corresponding to 
N-terminal region of DLC1-v1 and thus it is specific for two 
isoforms that originate from the promoter region that we 
found as hypermethylated in meningiomas: DLC1-v1 and 
DLC1-v3.
Fourteen tumor Sections (77 %) showed either a lack of, 
or low DLC1 expression. Moderate or high protein expres-
sion was clearly visible in 4 tumor samples: 1 meningothelial 
(GI), 1 atypical (GII) and 2 anaplastic (GIII) meningiomas 
and examples are presented in Fig. 2a.
When DLC1 promoter methylation was matched with 
expression status, 3/4 expression positive meningiomas 
showed methylation levels around 50 % or less, whereas 
13/14 negative tumor expression showed at least 70 % DNA 
methylation. When the mean DLC1 promot r DNA methyl-
ation level in expression positive and negative/low samples 
Active RHO-GTPases pull dow  assay
The status of RHO-GTPases activation was assessed using 
Active Rho Pull-Down and Detection Kit (Thermo/Pierce), 
according to manufacturer’s protocol.
Cells were seeded onto four 10 cm plates and transfected 
with one of the plasmid vectors (encoding shRNA target-
ing DLC1-v1 or shRNA control) in duplicates. 48 h after 
transfection the cells were washed with ice cold TBS, and 
lysed with cell lysis buffer. Each lysate was pooled from 
two 10 cm plates and centrifuged t 10,00 rpm or 2 min 
at 4 °C. Equal amounts of protein extracts were used for 
pull-down assay and incubated for 1 h at 4 °C with Rho-
tekin-RBD protein Sepharose beads. Pellets were washed 
three times with 0.4 ml of Lysis/Binding/Was  buffer and 
eluted with 50 μl of reducing sample buffer. The samples 
were boiled for 5 min at 95 °C, centrifuged at 13,000 rpm
for 5 min and analyzed by SDS-polyacrylamide gel electro-
phoresis. 25 μl of the sample was used per gel lane. Western 
blots were then carried out to detect the RHO-GTPases in 
the samples, using rabbit anti-Rho antib dy that reacts with 
RhoA, RhoB and RhoC, and which is part of the kit. Th  
same antibody was used to measure a total level f RHO-
GTPases on the cell extract by western blot in parallel.
Statistical analysis
Quantitative continuous variables were analyzed using e 
two-sided Mann–Whitney U test and the Kruskal–Wallis 
test when more than two groups of samples were compared. 
Alternatively, two-sided student’s t te t was use  when
Gaussian distribution was confirmed. A significance thresh-
old level p = 0.05 was used. Data were analyzed and visual-
ized using GraphPad Prism (GraphPad Software).
Results
Aberrant DLC1 DNA methylation in meningioma
The comparison of meningioma vs. normal m ningea  tis-
sue showed significantly higher DNA methylation in tumors 
at 6 probes clustered at the DLC1-v1 alternative promoter. 
These probes represent a differentially methylate  region 
(chr8:13372132-13,373142; hg19). Differences in DNA 
methylation levels for these probes between tumor and nor-
mal samples, measured as the differenc  of the m an beta-
value (proportion of methylated molecules, where 0 denotes 
lack of DNA methylation and 1 denotes comple e methyla-
tion), ranged from 0.216 to 0.417. Details are presented in 
Fig. 1 a, b.
Human Methylation 450-K array contains 81 methyla-
tion specific probes that span the entire DLC1 locus. This 
1 3
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in both datasets. DLC1 expression levels are significantly 
downregulated in meningiomas compared to normal menin-
ges, whereas they are comparable in benign and atypical/
anaplastic tumors.
We focused on gene annotation for these two particular 
platforms to verify which DLC1 express on variants are cov-
ered by the differentiating probes. Probes from GSE12530 
were described as common for three expression variants 1, 
2 and 4 (NM_182643, NM_006094, NM_001164271.1), 
whereas different Affymetrix probesets from GSE43290 
are designed for different DLC1 var ants. This includes two 
probesets that significantly differentiate meningioma vs. 
normal meninges; 220511_s_at probeset that cover variants 
was compared, significantly lower DNA methylation level 
in DLC1 immuno-reactive samples was fo nd (mean 40.88 
vs 80.29 %, p = 0.0092). This implies a relationship be w en 
promoter DNA methylation levels nd expression status of 
corresponding DLC1-v1/-v3 variants in tissue.
We also looked for DLC1 expression in the available 
microarray data at the Gene Expression Omnibus. Two 
data sets, analyzed with two different platforms were used: 
GSE12530 (CodeLink Human Whole Genome Bioarray
GE Healthcare/Amersham Bioscienc s, ~45600 genes) and 
GSE43290 (Human Genome U133A Array, Affymetrix, 
~14500 genes). DLC1 was found in 200 genes mos  d f-
ferentially expressed in meningiomas and normal meninges 
A
B C
Fig. 2 aExamples of immunohistochemical staining of DLC1-v1/-v3 
protein expression in meningiomas. Magnification ×400. b Compari-
son of DNA methylation levels in meningiomas with high/moderate 
DLC1 expression and meningiomas with none/poor DLC1 expression. 
 Compar g the relati e expression levels of DLC1v1 and DLC1v3 
measured by 220511_s_at probeset (HG U133A Array, Affymetrix), 
GSE43290 dat et. Horizontal lin s represent the mean value
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lower expression of DLC1-v2 compared to DLC1-v1 and 
DLC1-v3, but with an apparently lower RNA expression 
level of DLC1-v5 (p < 0.0001, Kruskal–Wallis test).
The role of DLC1-v1 silencing in meningioma cell line
To investigate the role of DLC1-v1downr gulation we per-
formed a knockdown experiment in KT21 cell line estab-
lished from human malignant meningioma [16 ]. Ini ially, 
we determined the expression level of different DLC1 vari-
ant in KT21 cells. DLC1-v1 appeared to be the predominant 
one, however DLC1-v5 also was found expressed in these 
cells (Fig. 4).
KT21 cells were transfected with plasmid vector con-
taining shRNA cassette targeting 5′ region of DLC1-v1/-
v3 using lipofectamine 2000, to decrease the expression 
level of these transcription variants. Control cells were 
transfected with the same vector type with non-effective 
shRNA cassette (sh control), available commercially. In the 
initial experiment transfected cells were analyzed by flow 
cytometry that showed relatively good transfection efficacy 
~60 % and sorted with cell sorter using GFP fluorescence. 
The effect of transfection with shRNA plasmid was tested 
on sorted cells. This revealed a decrease of DLC-v1 mRNA 
level up to 22 % of the expression level in control cells as 
well as visible protein level downregulation (Fig. 4).
Three experiments were performed on KT21 cells after 
transfection with plasmid vector targeting DLC1 expressi n 
to investigate the effect of gene downregulation on selected 
biological processes that are related to a known DLC1 
1 and 3 as well as 210762_s_at probes t that cover exons 
of variants 1, 2, 4 and 5. Importantly, tumor and menin-
ges samples revealed significantly different signal for the 
220511_s_at probeset that cover only the mRNA tran-
scripts originated from the alternative promoter region of 
DLC1-v1/-v3, that is commonly hypermethylated in menin-
giomas (Fig. 2).
Measuring expression levels of different DLC  variants 
in meninges and meningiomas
Since it has been previously shown that DLC1 transcrip-
tion variants are expressed in a tissue-dependent manner, 
we designed different sets of PCR primers specific for par-
ticular transcripts to measure their xpress on in normal 
meninges and meningiomas with qRT-PCR. This analys s 
included 4 additionally collected sections of snap-frozen 
normal meninges and 16 meningiomas (15 GI, 1 GII).
Expression levels of DLC1 ariants in normal menin-
geal samples varied somewhat betwe n individual samples. 
All gene variants were expressed, exc pt aria t 4 whi h 
was below qRT-PCR detection limits in near y all samples. 
DLC1-v1 was found to be the most expressed in normal 
meninges, as shown on Fig.3. The DLC1variant 1 was also 
the only one to be significantly down-regulated in menin-
giomas compared to meninges (6.5 fold change of expres-
sion p = 0.004), however, a small but insignificant decrease 
of DLC1-v5 expression was also observed (Fig. 3). Menin-
gioma samples had slightly var able expr ssion levels of 




Fig. 3 aComparing expression levels of different DLC1 transcription variants in normal meningeal sections. b–e: Comparing expr ssion levels
of particular DLC1 isoforms in normal meninges and meningiomas. Horizontal lines represent the mean value
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metabolic activity of the cells as observed in MTT test 
(p = 0.042).
Discussion
Downregulation of DLC1 in meningiomas was previously 
shown in a small study on 6 tumor samples. Importantly, 
this gene acts as a tumor suppressor and the transfection 
of primary meningioma cultured cells with normal DLC1 
results in a decrease of meningioma cell growth. A search 
of deposited microarray expression results also showed 
decreased DLC1 levels in meningiomas compared to normal 
activity: activation of RHO-GTPases, cell metabolic activ
ity and cell migration. As observed in active RHO-GTPases 
pull down assay transfection of KT21 cells with shRNA tar-
geting DLC-v1 resulted in the increased activity of RhoA, 
RhoB and RhoC as compared to control cells (Fig. 4.). As 
RHO-GTPases are known regulators of cell migration, par-
ticularly through ROCK kinase pathway th s r sult s in 
line with the outcome of the cell migr tion test. KT21 cells 
treated with shRNA against DLC-v1 where characterized 
by increased migration. These cells covered the cell-fre  
area in the woundheeling scratch assay significantly more 
quickly than control cells (p = 0.0044) (Fig. 4)  Transfec-






Fig. 4 a The expression of DLC1 transcription variants in KT21 
meningioma cells, qRT-PCR results. b Silencing of DLC1-v1 expres-
sion in KT21 cells through transfection with plasmid vector contain-
ing specific shRNA cassette as compared with cells transfected with 
control non-effective vector. Cells’ transfection efficacy assessed 
with flow cytometry, DLC1-v1 mRNA and protein level comparison 
between KT21 cells transfected with DCL1 specific (sh DLC1-v1) 
and non-specific shRNA vectors sh control. c Active RHO-GTPases 
pull-down assay in KT21 cells transfected with shRNA targeting 
DLC1 and control cells. RHO-GTPases were detected with antibody 
specific to RhoA, RhoB and RhoC.  Result of MTT test performed in 
KT21 cells transfected with shRNA targeting DLC1 and control cells. 
e The results of woundhealing assay performed in KT21 cells trans-
fected with shRNA targeting DLC1 and control cells. The examplary 
fields marked for the measurement of the migration distance. The com-
parison of migration distance of shDLC1-1 and sh-control KT21 cells.
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downregulation was observed [7]. In another study, frequent 
epigenetic downregulation of DLC1-v5 was identified in cer-
tain human cancers and a panel of different cell lines [9].
Microarray data from previously performed expres-
sion profiling of meningiomas and normal meninges, with 
Affymetrix U133 expression arrays (GEO GSE43290), 
showed that significantly decreased signal occurred in tumor 
samples for a probeset specific to DLC-v1 and DLC1-v3 iso-
forms that share the unique N-terminal region. These two 
isoforms are transcribed from the promoter region which we 
observed to be hypermethylated in meningiomas.
To determine the potential relationship between the pro-
moter methylation of the DLC1 promoter that we found 
with expression of DLC1-v1 and DLC1-v3 isoforms we per-
formed a series of immunohistochemical staining of menin-
giomas’ sections with the antibody specific to N-terminal 
region of DLC1-v1/-v3 isoforms. As clarified with the sup-
plier of this antibody, it does not detect the remaining DLC1 
protein isoforms. Low or no DLC1 protein expression was 
observed in a large proportion of tumor tissues, in accor-
dance with the mentioned microarray results. Additionally, 
a relationship between tissue immunoreactivity and DNA 
methylation was observed as the samples with positive 
DLC1-v1/-v3 staining showed significantly lower methyla-
tion level of the corresponding promoter region than DLC1 
negative ones.
The above findings indicate that isoforms DLC1-v1/-v3 
are downregulated in DNA methylation dependent manner 
in meningiomas and suggested that these isoforms may be 
substantially relevant in meninges and their tumorigenesis. 
When we compared mRNA expression levels of 5 different 
DLC1 isoforms in normal meninges, it appeared that DLC1-
v1 was the one most expressed. This isoform was also the 
only one that is significantly downregulated in meningeal 
tumors. We did not observe any such significant downregu-
lation of DLC-v2, that is highly expressed transcription vari-
ant in most of previously investigated tissue types.
The promoter region of DLC1-v1/v3 have been previ-
ously described. The binding sites of particular transcription 
factors, including TP53, STATs, HSF and E2F, were identi-
fied and promoter activity of this region was confirmed by 
the luciferase reporter assay [9]. The epigenetic DNA meth-
ylation dependent regulation of this promoter was consid-
ered as rather unlikely, because the region does not meet 
the criteria of CpG island and the expression of DLC1-v1 
was not restored after 5-aza-2′-deoxycytidine treatment in 
selected cell lines [7, 9]. However, it is worth noting that 
the exact DNA methylation pattern of these regions was not 
determined in cell lines and tissue samples, so it is not clear 
if resumption of gene expression could be expected in the 
tested cells by targeting DNA methylation. It is also seen 
that, in general, DNA methylation of non-CpG island gene 
promoters can affect gene expression [23, 24].
meninges in different publicly accessible d t se s. These 
preliminary data supported the idea that DLC1 is a tumor 
suppressor that is silenced in meningiomas, similar to other 
human tumors such as nasopharynge l, pancreatic, colon, 
prostate and liver cancer [4, 6, 17 –19 ].
DLC1 downregulation in tumors can arise from genomic 
mutation or be due to aberrant epigenetic r gulatio  includ-
ing high DNA methylation levels at th  g ne promoter 
region, as it is frequently observed in v ious tumors [6, 
17 –19 ].
Interestingly, a previous study on DLC1 downregula-
tion in meningiomas demonstrated a lack of prom r DNA 
hypermethylation in tumors. It was stated hat the g ne is 
not inactivated via DNA methylation mechanism [10 ]. In 
our study, we identified DLC1 as being frequently hyp-
methylated in meningiomas from genom -wide com-
parisons of different mening omas and n rma  meninges 
sections. At first glance this may seem to be contrary to pre-
vious report, however, it appears that the complex structure 
and regulation of the DLC1 genomic loci can explain this 
inconsistency.
The DLC1 gene encodes 5 different protein isoforms and 
gene transcription can originate from different promoter 
regions (Fig. 1 a). This regulation mechanism s common 
to all DLC family members of RHO GTP-ases and dif-
ferent identified isoforms of DLC2 (STARD13) and DLC3 
(STARD8) are transcribed from alternative promote . DLC-
1 isoforms, except from DLC1-v3 [7], encode functi nal 
RHO GTPases that differ in N-terminal region and share 
the same functional domains [3]. It seems that they differ in 
subcellular localization. DLC1-v1and DLC1-v2  found 
at focal adhesion sites, DLC1-v3 in the cytoplasm, whereas 
DLC-i4 is a putative mitochondrial protein [7, 9]. DLC-v2 
was also observed in adherence junctions, cytosol a d the 
nucleus [20 –22]. The exact differences in b ol gical roles f 
the different isoforms remain elusive, however, tumor sup-
pressor activity was confirmed for different isoforms encod-
ing functional RhoGAP domain [7, 9].
Previous studies on DLC1 isoforms 1–3 and 5 howed 
that they are all expressed in various human tissues, includ-
ing brain [9]. However, actual expression l vels of d fferent 
gene isoforms seem to be tissue dependent [7, 8 ]. Human 
spleen, liver and colon tissues show th  highest level f
DLC1 isoform 2, the thyroid shows comparable levels of 
isoforms 1 and 2, whereas nearly exclusive expression of 
isoform 1 was found in the heart [7].
The majority of cancer studies on DLC1 silencing, does 
not address the problem of the complex gene transcri tion 
nor the expression of alternative soforms, but ar  instead 
focused on the expression of the gene variant 2 or th y utilize 
the qRT-PCR primers or antibodies not specific to given iso-
forms. The expression of different DLC1 isoforms was deter-
mined in hepatocarcinoma, whe e DLC1-v2, but not DLC1-v1 
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to tumorigenesis and that the DNA methylation of the 
corresponding promoter regions may play a role in gene 
silencing. We believe that our study indicates a promis-
ing direction for further research, because different tran-
scription variants of many known tumor-related genes can 
be regulated via alternative promoters. The well-known 
examples are TP53, TP63, TP73, CDKN1A, CDKN2A or 
PTCH1 [28 , 29]. In general, the role of abnormal epigen-
etic regulation of alternative gene promoters in cancer is 
poorly understood.
Acknowledgments We thank Dr. Piotr Hołownia for proofreading 
the manuscript. We thank prof. Christian Mawrin and prof. Elmar 
Kirches for sharing KT21 meningioma cells. This work was supported 
by the National Science Centre Grant UMO-2011/01/D/NZ5/02798.
Compliance with ethical standards
Conflict  of  interest The authors report no potential conflicts of 
interest.
Open Access Thi  article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://cre-
ativecommons.org/licenses/by/4.0/), which p rmits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, 
Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO 
classification of tumours of the central nervous system. Acta Neu-
ropathol 114:97–109
 2. Mawrin C, Perry A (2010) Pathological classification and molec-
ular genetics of meningiomas. J Neurooncol 99:379–391
 3. Braun AC, Olayioye MA (2015) Rho regulation: DLC proteins in 
space and time. Cell Signal 27:1643–1651
 4. Liao YC, Lo SH (2008) Deleted in liver cancer-1 (DLC-1): 
a tumor suppressor not just for liver. Int J Biochem Cell Biol 
40:843–847
 5. Barras D, Widmann C (2014) GAP-independent functions of 
DLC1 in metastasis. Cancer Metastasis Rev 33:1–14
 6. Xue Y-Z, Wu T-L, Wu Y-M, Sheng Y-Y, Wei Z-Q, Lu Y-F, Yu 
L-H, Li J-P, Li Z-S (2013) DLC-1 is a candidate biomarker meth-
ylated and down-regulated in pancreatic ductal adenocarcinoma. 
Tumour Biol 34:2857–2861
 7. Ko FCF, Yeung YS, Wong CM, Chan LK, Poon RTP, Ng IOL, 
Yam JWP (2010) Deleted in liver cancer 1 isoforms are distinctly 
expressed in human tissues, functionally different and under dif-
ferential transcriptional regulation in hepatocellular carcinoma. 
Liver Int 30:139–148
 8. Sabbir MG, Wigle N, Loewen S, Gu Y, Buse C, Hicks GG, Mowat 
MRA (2010) Identification and characterization of Dlc1 isoforms 
in the mouse and study of the biological function of a single gene 
trapped isoform. BMC Biol 8:17
 9. Low JSW, Tao Q, Ng KM et al (2011) A novel isoform of the 
8p22 tumor suppressor gene DLC1 suppresses tumor growth and 
is frequently silenced in multiple common tumors. Oncogene 
30:1923–1935
Because DLC1-v3 lack the functional d mains it is con-
sidered as nonfunctional or putative regulat ry prot in [7]. 
In turn, DLC1-v1 that is fully active protein, significantly 
downregulated in meningiomas turns ou  to be the most el-
evant form of DLC1 protein in neoplas c tr nsformation of 
meninges. The onco-suppressiv  ole of this protein v r ant 
was shown previously in hepatocel ul  carcinoma (HCC) 
cell lines. DLC1-v1 inhibited stress fibre formation and sup-
pressed growth of HCC cells [7]. In another study, the over-
expression of this variant in HCT116 color ctal carcinoma 
cells and KYSE510 cells from esophageal cancer resulted 
in suppressed tumor cell colony forma ion [9]. Together 
this is concordant with the results of functional analysis 
of the mutations that were found in N-t minal domain of 
DLC-v1 in patients with sporadic congenital heart disease. 
These mutations, disturbing DLC1 structure, appeared to 
increase cell migration of human umbilical vein endothelial 
cells (HUVEC) and human bone marrow endothelial cells 
60 (HBMEC-60) [25]. In our hands, targeting of DLC1-v1 
with specific shRNA in KT21cells established from human 
malignant meningioma resulted in enhanced activity of 
RhoA/RhoB/RhoC GTPases as shown in active RHO pull 
down assay and increased cell migration in scratch assay. 
This results corroborates the previous report and confirms 
that DLC1-v1act as tumor suppressor.
DLC1 regulates cell migration through the inhibition of 
RHO-GTPases/ROCK kinase signaling as well as in RHO-
independent manner. Both pathways lead to the cytoskeletal 
reformation and the changes of focal adhesion and intercel-
lular junctions, especially adherence junctions maintained 
by cadherins [3]. I terestingly, in line with the obser ation 
of the aberrant DLC1 expression in meningiomas, both focal 
adhesion and adherence junction formation processes were 
found among the most disturbed in meningioma pathogen-
esis and progression [26, 27].
In summary, our results show for the first time that CpGs 
of the DLC1-v1 alternative promoter is frequently hyper-
methylated in tumors of meningeal origin. Significantly 
higher methylation levels of th s region was observed in 
meningiomas without DLC-1 protein expression compared 
to immunoreactive tumors. The remain ng DLC1 alternative 
promoters are unmethylated. This includes the promoter of 
DLC1-v2 that was reported as being hypermethylated in 
diverse cancers. This result is consist nt with th  previous 
report showing lack of DLC1 methylation in meningiomas, 
because it was focused on the DNA methylation at the pro-
moter of DC1-i2 only [10 ].
Additional comparison of mRNA expressio  lev ls of
all known DLC1 isoforms showed that DLC1-v1 is the 
one most expressed in normal meninges and its expression 
level is most notably reduced in meningioma . This allows 
for a conclusion that in meningiomas, the decreased DLC1 
isoform 1, (with proven suppressor activity), contributes 
1 3
J Neurooncol (2016) 130:473–484 483
20. Zhou X, Thorgeirsson SS, Popescu NC (2004) Restoration of 
DLC-1 gene expression induces apoptosis and inhibits both cell 
growth and tumorigenicity in human hepatocellular carcinoma 
cells. Oncogene 23:1308–1313
21. Yuan B-Z, Jefferson AM, Millecchia L, Popescu NC, Reynolds 
SH (2007) Morphological changes and nuclear translocation of 
DLC1 tumor suppressor protein precede apoptosis in human non-
small cell lung carcinoma cells. Exp Cell Res 313:3868–3880
22. Tripathi V, Popescu NC, Zimonjic DB (2012) DLC1 interaction 
with -Catenin stabilizes adherens junctions and enhances DLC1 
antioncogenic activity. Mol Cell Biol 32:2145–2159
23. Marx A, Kahan T, Simon I (2013) Integrative analysis of methy-
lome and transcriptome reveals the importance of unmethyl-
ated CpGs in non-CpG island gene activation. Biomed Res Int 
2013:785731
24. Han H, Cortez CC, Yang X, Nichols PW, Jones PA., Liang G 
(2011) DNA methylation directly silences genes with non-CpG 
island promoters and establishes a nucleosome occupied pro-
moter. Hum Mol Genet 20:4299–4310
25. Lin B, Wang Y, Wang Z et al (2014) Uncovering the rare variants 
of DLC1 isoform 1 and their functional effects in a chinese spo-
radic congenital heart disease cohort. PLoS One 9:e90215
26. Wang X, Gong Y, Wang D et al (2012) Analysis of gene expres-
sion profiling in meningioma: deregulated signaling pathways 
associated with meningioma and EGFL6 overexpression in 
benign meningioma tissue and serum. PLoS One 7:1–10
27. Carlos J, Gómez I, Orgueira AM (2014) An integrative analysis of 
meningioma tumors reveals the determinant genes and pathways 
of malignant transformation. Front Oncol 4:1–12
28. Landry JR, Mager DL, Wilhelm BT (2003) Complex controls: 
the role of alternative promoters in mammalian genomes. Trends 
Genet 19:640–648
29. Blackburn J, Roden DL, Ng R, Wu J, Bosman A, Epstein RJ 
(2015) Damage-inducible intragenic demethylation of the human 
TP53 tumor suppressor gene is associated with transcription from 
an alternative intronic promoter. Mol Carcinog. doi:10.1002/
mc.22441
10. Hankins GR, Sasaki T, Lieu A-S, Saulle D, Karimi K, Li JZ, 
Helm GA (2008) Identification of the deleted in liver cancer 1 
gene, Dlc1, as a candidate meningioma tumor suppressor. Neuro-
surgery 63:771–781
11. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman 
K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, 
Carrión-Grant G, Yılmaz B, Conor Gr MG (2013) Genomic 
analysis of non-NF2 meningiomas reve s mutations in TRAF7, 
KLF4, AKT1, and SMO. Science 339:1077–1080
12. Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic 
sequencing of meningiomas identifies oncogenic SMO and AKT1 
mutations. Nat Genet 45:285–289
13. O’Leary NA, Wright MW, Brister JR et a  (2015) Reference 
sequence (RefSeq) database at NCBI: current status, taxo-
nomic expansion, and functional annotation. Nucleic Acids Res 
44:733–745
14. Teschendorff AE, Marabita F, Lechner M, Bartl t T, Tegner J, 
Gomez-cabrero D, Beck S (2013) Gene expression A beta-mix-
ture quantile normalization method for correcting probe design 
bias in Illumina Infinium 450k DNA methylation data. Bioinfor-
matics 29:189–196
15. Pfister C, Tatabiga MS, Roser F (2011) Selection of suitable refer-
ence genes for quantitative real-time polymerase chain reaction in 
human meningiomas and arachnoidea. BMC Res Notes 4:275
16. Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada 
K, Miyaki M (1989) Establishment of a human malignant 
meningioma cell line with amplified c-myc oncogene. Cancer 
64:2243–2249
17. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC 
(2006) Aberrant methylation and deacetylation of deleted in liver 
cancer-1 gene in prostate cancer: potential clinical applications.
Clin Cancer Res 12:1412–1419
18. Feng X, Ren C, Zhou W et al (2013) Promoter hypermethylation 
along with LOH, but not mutation, contribut s to inactivation of 
DLC-1 in nasopharyngeal carcinoma. Mol Carcinog 870:1–13
19. Dai Z, Jin Y (2013) Promoter methylation of the DLC-1 gene 
and its inhibitory effect on human colon cancer. Oncol Rep 
30:1511–1517
1 3
J Neurooncol (2016) 130:473–484484
